Literature DB >> 15450382

HSV shedding.

S L Sacks1, P D Griffiths, L Corey, C Cohen, A Cunningham, G M Dusheiko, S Self, S Spruance, L R Stanberry, A Wald, R J Whitley.   

Abstract

Viral shedding of HSV occurs frequently in infected individuals. HSV is shed asymptomatically from multiple anatomical sites and shedding, like exposure, is a significant risk for transmission. However, the relationship between shedding frequency, viral titer and transmission is unknown. HSV-2 shedding is affected by the site and time since acquisition of infection. The advent of sensitive PCR techniques has shown that the magnitude and frequency of viral shedding is higher than shown previously with viral culture techniques. It has also clearly demonstrated that suppressive (daily) antiviral therapy reduces clinical and subclinical reactivation rates, and has been successfully used in the prevention of recurrent oral and genital HSV infections. A recent study has demonstrated that daily antiviral therapy with valaciclovir can significantly reduce transmission of HSV-2 between discordant heterosexual couples in monogamous relationships.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450382     DOI: 10.1016/j.antiviral.2004.06.004

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  27 in total

1.  The herpes simplex virus 1 UL51 protein interacts with the UL7 protein and plays a role in its recruitment into the virion.

Authors:  Richard J Roller; Rachel Fetters
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

2.  A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.

Authors:  Mayla Hsu; Meropi Aravantinou; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Nina Derby; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

3.  High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients.

Authors:  Laurent Andréoletti; Emmanuel Piednoir; Jérôme Legoff; Véronique Brodard; Isabelle Beguinot; Christophe Strady; Christine Rouger; Christophe Piketty; Ali Si-Mohamed; Michel Daniel Kazatchkine; Jean-Elie Malkin; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi.

Authors:  Balbina J Plotkin; Ira M Sigar; Vaibhav Tiwari; Scott Halkyard
Journal:  J Vis Exp       Date:  2016-07-06       Impact factor: 1.355

5.  Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.

Authors:  Tina M Cairns; Zhen-Yu Huang; John R Gallagher; Yixin Lin; Huan Lou; J Charles Whitbeck; Anna Wald; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

6.  A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.

Authors:  Manish Kumar; James M Hill; Christian Clement; Emily D Varnell; Hilary W Thompson; Herbert E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

7.  The diagnosis of genital herpes - beyond culture: An evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology.

Authors:  S Ratnam; A Severini; G Zahariadis; M Petric; B Romanowski
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

8.  Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study.

Authors:  Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso
Journal:  BMC Infect Dis       Date:  2009-04-01       Impact factor: 3.090

9.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099

10.  A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.

Authors:  Federica Crostarosa; Meropi Aravantinou; Onome J Akpogheneta; Edith Jasny; Andrew Shaw; Jessica Kenney; Michael Piatak; Jeffrey D Lifson; Aaron Teitelbaum; Lieyu Hu; Anne Chudolij; Thomas M Zydowsky; James Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.